Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
about
Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.[Management of different cardiovascular risk factors with a combination tablet (polypill)].Cardiovascular diseases in mega-countries: the challenges of the nutrition, physical activity and epidemiologic transitions, and the double burden of disease.Could patents interfere with the development of a cardiovascular polypill?Starting the polypill: the use of a single age cut-off in males and females.Polypills for the prevention of Cardiovascular diseases.The Rotterdam Study: 2018 update on objectives, design and main results.Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries.
P2860
Q30235416-42BA230E-5774-458C-81CD-EFC774B6AC45Q36322893-9452A548-84D4-4EE0-8927-4A6DF735A1DAQ37100330-B5170C02-8BAE-494E-B73A-B63988090EA5Q37189186-8F44F2F2-72D4-4025-8C61-38AD50604018Q37641217-02548CA7-A40D-4FB7-AAF2-A941B6174AC0Q38809466-685D4CFF-FAD1-4BF2-A602-0BE7B7A28F7BQ47121939-BACEDDDF-B16C-406E-A71C-F3752EA35343Q55434208-B14FE10F-CE24-4393-A917-ED8D15C613FA
P2860
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Cost-benefit analysis of the p ...... cardial infarction and stroke.
@en
type
label
Cost-benefit analysis of the p ...... cardial infarction and stroke.
@en
prefLabel
Cost-benefit analysis of the p ...... cardial infarction and stroke.
@en
P2093
P2860
P1476
Cost-benefit analysis of the p ...... cardial infarction and stroke.
@en
P2093
David Taylor
Johannes Michiel Luteijn
Nicholas J Wald
Peter Oppenheimer
P2860
P2888
P304
P356
10.1007/S10654-016-0122-1
P577
2016-03-05T00:00:00Z